智通财经APP获悉，香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山(00874)3万 股，每股作价18.112港元，总金额约为54.34万港元。增持后最新持股数目为1101.92万股，最新持股比 例为5.01%。 ...

Group 1 - The company has approved the establishment of the Guangzhou Liwan Guangyao Venture Capital Fund Partnership (Limited Partnership) through its subsidiary, Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership) [1] - The partnership involves collaboration with Guangzhou Guangyao Capital Private Fund Management Co., Ltd., Guangzhou Angel Investment Mother Fund Venture Capital Partnership (Limited Partnership), and Guangzhou Liwan District Industrial Investment Fund Partnership (Limited Partnership) [1] - The partnership agreement has been signed recently, with no changes to the main content compared to the previous announcement [2] Group 2 - The establishment of the Guangzhou Liwan Guangyao Fund is pending necessary registration and filing procedures, which introduces some uncertainties in the implementation process [2] - The company will continue to monitor the progress of this investment and fulfill its information disclosure obligations in accordance with relevant laws and regulations [2]

致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2026年1月2日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定 ...

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定 ...

证券代码：600332 证券简称：白云山 公告编号：2025-098 广州白云山医药集团股份有限公司 关于附属企业参与投资设立广州荔湾广药创业投资 基金合伙企业（有限合伙）暨关联交易的进展公告 （"天使母基金"）、广州市荔湾区产业投资基金合伙企业（有限合伙）（"荔 湾产投基金"）合作设立广州荔湾广药创业投资基金合伙企业（有限合伙）（暂 定名，以工商登记为准，"广药荔湾基金"）并签署《广州荔湾广药创业投资基 金合伙企业（有限合伙）合伙协议》（"《合伙协议》"）。具体内容详见本公 司于 2025 年 12 月 23 日披露的编号为 2025-092 的公告（"此前公告"）。 二、进展情况 近日，广药二期基金与广药资本、天使母基金、荔湾产投基金正式签署了《合 伙协议》。《合伙协议》主要内容较此前公告并无任何变更，具体内容详见此前 公告。 三、风险提示 广药荔湾基金尚需履行工商注册登记、中国证券投资基金业协会登记备案等 手续，实施过程尚存在不确定性。本公司将持续关注本次投资的实施进展，并严 格按照有关法律、法规要求及时履行信息披露义务。敬请广大投资者理性投资， 注意投资风险。 本公司董事会及全体董事保证本公告内容不存 ...

廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年12月31日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 參與設立廣藥廣開基金和廣藥荔灣基金 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年12月22日之公告（「該公告」），內 容有關本公司附屬企業廣藥二期基金參與設立廣藥廣開基金和廣藥荔灣基金之關連交易。除另有界 定外，本公告所用詞彙與該公告所界定者具有相同涵義。 董事會欣然宣佈於2025年12月31日，廣藥二期基金與廣藥資本、天使母基金、荔灣產投基金訂立了 有關設立廣藥荔灣基金的合伙協議二。合伙協議二於同日正式生效，合夥協議二的主要條款並無任 何變更。合夥協議二的主要條款及本次投資詳情載於該公告。 ...

Meeting Overview - The third extraordinary general meeting of shareholders was held on December 30, 2025, at the company's meeting room in Guangzhou, Guangdong Province [2] - The meeting was convened by the board of directors and chaired by Mr. Li Xiaojun, the chairman of the company [2][3] - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2] Attendance - Out of 10 current directors, 9 attended the meeting, with Executive Director Mr. Cheng Hongjin absent due to official duties [3] - The company’s board secretary, Ms. Huang Xuezheng, and other senior management, as well as legal witnesses and vote counters, were present [3] Resolutions - Two ordinary resolutions were passed: 1. Approval for Guangzhou Pharmaceutical Co., Ltd. to conduct accounts receivable asset securitization [4] 2. Approval for the completion of fundraising investment projects and the permanent replenishment of working capital with surplus raised funds [4] - All resolutions received more than half of the votes from the total shares represented at the meeting [5] Legal Witnessing - The meeting was witnessed by Hong Kong Central Securities Depository Co., Ltd., lawyers, and shareholder representatives who acted as vote counters and monitors [5] - The legal opinion was provided by Beijing Zhonglun (Guangzhou) Law Firm, confirming the legality and validity of the meeting's procedures and resolutions [5]

Group 1 - The core announcement is that the company will hold its third extraordinary general meeting of shareholders on December 30, 2025 [1] - The agenda includes the proposal for Guangzhou Pharmaceutical Holdings to conduct accounts receivable asset securitization [1] - Another agenda item is the proposal for the settlement of fundraising investment projects and the permanent replenishment of working capital with surplus raised funds [1]

Core Viewpoint - The consumer sector has faced significant challenges in the past year, with many sub-sectors experiencing declines despite overall market growth. The focus on domestic demand and consumption has not translated into positive performance for many consumer-related industries [1][5]. Consumer Sector Performance - In the first half of the year, 10 out of 16 declining industries were from the consumer sector, indicating a broader trend of underperformance [1]. - The white liquor sector, a key component of the consumer market, has seen a year-to-date decline of 12.44%, with major brands like Wuliangye experiencing significant drops in revenue and profit [6][9]. - The professional chain sector has been particularly hard-hit, with a year-to-date decline of 14.72%, exemplified by the struggles of companies like Renrenle [16][20]. White Liquor Sector - The white liquor industry is facing its eighth consecutive year of production decline, with both volume and price dropping simultaneously [10]. - Wuliangye reported a 10.26% decline in revenue and a 13.72% drop in net profit for the first three quarters, marking its first negative growth in a decade [9]. - The industry is shifting from a growth-driven model to one focused on consumer choice, with a need for companies to adapt to changing consumer preferences [15]. Professional Chain Sector - The professional chain sector is experiencing a crisis, with many physical stores closing and traditional business models failing [16][20]. - Renrenle, once a leading private supermarket, has seen its market value plummet and is now facing delisting due to ongoing financial struggles [21][24]. - The shift towards online shopping and personalized consumer demands has further exacerbated the challenges faced by traditional retail chains [24][25]. Non-White Liquor Sector - The non-white liquor sector, including beer and wine, has also faced declines, with the beer segment seeing a notable drop in sales and profits [27][32]. - Budweiser APAC reported an 8.2% decline in domestic sales and a 24.4% drop in net profit, reflecting broader industry challenges [32][33]. - The market is witnessing a trend of cross-industry competition, with liquor companies diversifying into new beverage categories [34]. Publishing Sector - The publishing industry has shown resilience despite a 10.4% decline in the overall market for printed books, with listed companies managing to increase net profits by 14.65% [43][44]. - However, leading companies like Zhongwen Media are struggling, with significant revenue and profit declines due to changes in educational material procurement policies [45][48]. Seasoning Sector - The seasoning industry has faced a 6.04% decline, with companies like Qianhe Flavor struggling due to falling revenues and a loss of consumer trust [51][55]. - The industry is experiencing a shift in consumer preferences and increased competition, necessitating a reevaluation of business strategies [60]. Traditional Chinese Medicine Sector - The traditional Chinese medicine sector is facing challenges, with companies like Pian Zai Huang reporting significant declines in revenue and profit due to rising costs and regulatory pressures [61][66]. - The industry is undergoing a transformation as companies seek to innovate and diversify their product offerings [70]. Digital Media Sector - The digital media industry has seen a 4.95% decline, with companies like Mango TV reporting significant drops in revenue and profit due to changing consumer behaviors and market dynamics [71][74]. - The sector is grappling with the need to adapt to new content consumption trends while facing pressure from traditional advertising models [75]. Kitchen and Bathroom Appliances Sector - The kitchen and bathroom appliance sector has experienced a 4.11% decline, largely due to reduced demand from the real estate market [78][79]. - Companies like Boss Electric are facing revenue declines for the first time in years, highlighting the challenges of adapting to a changing market landscape [79][80]. White Goods Sector - The white goods sector has seen a 2.02% decline, with major players like Gree Electric facing significant revenue and profit pressures due to increased competition and market saturation [83][84]. - The industry is shifting towards a focus on product quality and brand strength as external stimuli diminish [88]. Hotel and Restaurant Sector - The hotel and restaurant sector has faced a 1.37% decline, with revenue pressures stemming from changing consumer spending habits and increased competition from online platforms [89][92]. - Companies are beginning to adopt more refined operational strategies to navigate the challenging market environment [96].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 北京市中倫（廣州）律師事務所關於廣州白雲山醫藥集團股份有限公司2025年第三次臨時股東會的法 律意見書之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年12月30日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 北京市中伦（广州）律师事务所 关于广州白云山医药集团股份有限公司 2025 年第三次临时股东会的 法律意见书 二〇二五年十二月 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《 ...